| Literature DB >> 19110021 |
Cinzia Remondo1, Vittore Cereda, Sven Mostböck, Helen Sabzevari, Alex Franzusoff, Jeffrey Schlom, Kwong-Y Tsang.
Abstract
Tumor-associated antigens are weakly immunogenic. Human carcinoembryonic antigen (CEA) is overexpressed on a wide range of human carcinomas and represents an attractive target for cancer immunotherapy. This study analyzes the ability of a Saccharomyces cerevisiae vector containing the transgene encoding CEA (yeast-CEA) to activate human dendritic cells (DCs) and stimulate CEA-specific T-cell responses. We demonstrate for the first time that treatment with yeast-CEA can activate human DCs, resulting in increases in surface expression of CD80, CD83, CD54, CD58, and MHC class II, and increased production by DCs of IL-12p70, TNF-alpha, IFN-gamma, IL-8, IL-2, IL-13, IL-10, and IL-1beta. We also show that human DCs treated with yeast-CEA can activate CEA-specific T-cell lines and can act as antigen-presenting cells (APCs) to generate CEA-specific T-cell lines capable of lysing CEA(+) human tumor cells. Gene expression profiles of human DCs treated with yeast-CEA show increased expression of numerous genes involved in the production of chemokines and cytokines and their receptors, and genes related to antigen uptake, antigen presentation, and signal transduction.Entities:
Mesh:
Substances:
Year: 2008 PMID: 19110021 PMCID: PMC3518400 DOI: 10.1016/j.vaccine.2008.12.002
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641